Company profile for Prothena

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Prothena is a clinical-stage neuroscience company focused on the discovery and development of novel therapies with the potential to fundamentally change the course of devastating neurological disorders. We are advancing a pipeline of therapeutic candidates for a number of indications and novel targets including Parkinson’s disease and other related synucleinopathies (prasinezumab, PRX002/RG7935) and ATTR amyloidosis (PRX0...
Prothena is a clinical-stage neuroscience company focused on the discovery and development of novel therapies with the potential to fundamentally change the course of devastating neurological disorders. We are advancing a pipeline of therapeutic candidates for a number of indications and novel targets including Parkinson’s disease and other related synucleinopathies (prasinezumab, PRX002/RG7935) and ATTR amyloidosis (PRX004), as well as tau, and TDP-43 where our scientific understanding of disease pathology can be leveraged.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Ireland
Address
Address
77 Sir John Rogerson’s Quay, Block C Grand Canal Docklands Dublin 2, D02 T80...
Telephone
Telephone
+353 1 236 2500
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251212675747/en/Prothena-Announces-Board-of-Directors-Update

BUSINESSWIRE
12 Dec 2025

https://www.businesswire.com/news/home/20251119275479/en/Prothena-Announces-Poster-Presentation-on-its-TDP-43-CYTOPE-Program-at-Neuroscience-2025

BUSINESSWIRE
19 Nov 2025

https://www.businesswire.com/news/home/20251111691007/en/Prothena-Highlights-Phase-2-Data-for-Coramitug-Formerly-PRX004-Published-in-Circulation-Official-Journal-of-AHA

BUSINESSWIRE
11 Nov 2025

https://www.businesswire.com/news/home/20251106884802/en/Prothena-Reports-Third-Quarter-2025-Financial-Results-and-Business-Highlights

BUSINESSWIRE
06 Nov 2025

https://www.businesswire.com/news/home/20251030524160/en/Prothena-to-Report-Third-Quarter-2025-Financial-Results-on-November-6

BUSINESSWIRE
30 Oct 2025

https://www.businesswire.com/news/home/20251001695629/en/Prothenas-Partner-Bristol-Myers-Squibb-Obtains-Fast-Track-Designation-from-the-U.S.-FDA-for-BMS-986446-PRX005-an-Anti-MTBR-Tau-Targeting-Antibody-for-the-Treatment-of-Alzheimers-Disease

BUSINESSWIRE
01 Oct 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty